Fundz

EyePoint Pharmaceuticals Appoints Ramiro Ribeiro as Chief Medical Officer

PUBLIC · EYPTMar 04, 2024

Position

Chief Medical Officer

Company

EyePoint, Inc.

Ramiro Ribeiro
rribeiro@eyepointpharma.com
WatertownBiotechnologyHealthcareHealth CareTherapeuticsPharmaceutical

Description

EyePoint Pharmaceuticals, Inc. appoints Ramiro Ribeiro, M.D., Ph.D. as Chief Medical Officer to succeed Dario Paggiarino, M.D

Quick answer

EyePoint Pharmaceuticals Appoints Ramiro Ribeiro as Chief Medical Officer (March 4, 2024). EyePoint, Inc. is based in Watertown, Massachusetts, United States.

Who is the new Chief Medical Officer at EyePoint, Inc?
EyePoint, Inc. named Ramiro Ribeiro Chief Medical Officer, announced March 4, 2024.
What did EyePoint, Inc. announce on March 4, 2024?
EyePoint Pharmaceuticals, Inc. appoints Ramiro Ribeiro, M.D., Ph.D. as Chief Medical Officer to succeed Dario Paggiarino, M.D
What does EyePoint, Inc. do?
EyePoint Pharmaceuticals, Inc. is committed to developing and commercializing therapeutics to help improve the lives of patients with serious retinal diseases.
Where is EyePoint, Inc. based?
EyePoint, Inc. is based in Watertown, Massachusetts, United States.
Which similar companies made leadership changes around the same time?
Madrigal Pharmaceuticals (February 28, 2024), AbbVie Inc. (February 20, 2024), Corvus Pharmaceuticals, Inc. (February 6, 2024) and Apollomics (March 4, 2024) also announced leadership changes within 45 days of EyePoint, Inc.

Source: Fundz verified event record.

Other recent leadership changes in Healthcare and Therapeutics

Executive moves at companies in the same sectors within 45 days, from Fundz verified event records.

Who to call at EyePoint, Inc., and when

A new leader at EyePoint, Inc. brings new priorities and often new vendors. The first weeks are when they listen.

  • An alert the day EyePoint, Inc. raises, hires an executive or expands, scored against what you sell
  • The decision-makers there, with verified emails
  • Who you already know at EyePoint, Inc., from your own LinkedIn network

Works inside ChatGPT and Claude. Ask who to call at EyePoint, Inc.. With Fundz connected, it knows.

Watch Fundz in
See plan options
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

Company Information

Company

EyePoint, Inc.

Location

480 PLEASANT STREET

Watertown, Massachusetts, United States

About

EyePoint Pharmaceuticals, Inc. is committed to developing and commercializing therapeutics to help improve the lives of patients with serious retinal diseases.

AI made execution free. Knowing first is the whole game now.

Fundz sees it the moment EyePoint, Inc. changes its leadership, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Related People

Jay
Likely contact at this company
••••••••@••••••••

See Jay's verified email →

Create an account to reveal verified emails
Predictive Intelligence
Strategic

ML-powered predictions for EyePoint, Inc.'s next move

Learn about Strategic plan

EyePoint, Inc. changed its leadership. Fundz had it the day it was filed, with the decision-maker at the company attached.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.